Arcutis Biotherapeutics (ARQT) Competitors

Arcutis Biotherapeutics (NASDAQ:ARQT) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

Does the MarketBeat Community favor ARQT or INVA?

Innoviva received 242 more outperform votes than Arcutis Biotherapeutics when rated by MarketBeat users. However, 63.74% of users gave Arcutis Biotherapeutics an outperform vote while only 57.69% of users gave Innoviva an outperform vote.

Company	Underperform	Outperform
Arcutis Biotherapeutics	Outperform Votes 58 63.74%	Underperform Votes 33 36.26%
Innoviva	Outperform Votes 300 57.69%	Underperform Votes 220 42.31%

Does the media refer more to ARQT or INVA?

In the previous week, Arcutis Biotherapeutics had 9 more articles in the media than Innoviva. MarketBeat recorded 12 mentions for Arcutis Biotherapeutics and 3 mentions for Innoviva. Innoviva's average media sentiment score of 1.31 beat Arcutis Biotherapeutics' score of 0.64 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innoviva	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, ARQT or INVA?

Arcutis Biotherapeutics has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500.

Do analysts rate ARQT or INVA?

Arcutis Biotherapeutics presently has a consensus price target of $13.33, suggesting a potential upside of 42.60%. Given Arcutis Biotherapeutics' higher probable upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Innoviva	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is ARQT or INVA more profitable?

Innoviva has a net margin of 44.00% compared to Arcutis Biotherapeutics' net margin of -150.51%. Innoviva's return on equity of 33.26% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-150.51%	-145.41%	-51.04%
Innoviva	44.00%	33.26%	18.05%

Which has preferable valuation and earnings, ARQT or INVA?

Innoviva has higher revenue and earnings than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$132.06M	8.20	-$262.14M	-$2.93	-3.19
Innoviva	$330.50M	3.76	$179.72M	$2.22	8.95

Do insiders & institutionals believe in ARQT or INVA?

99.1% of Innoviva shares are owned by institutional investors. 9.5% of Arcutis Biotherapeutics shares are owned by insiders. Comparatively, 1.4% of Innoviva shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Innoviva beats Arcutis Biotherapeutics on 11 of the 18 factors compared between the two stocks.